All In Biotech

Drug Trial Radar · NCT06663748

ARX788 in HER2-positive Metastatic Breast Cancer Patients

Evaluate the Efficacy and Safety of ARX788 Given Every 6 Weeks in Patients With HER2-positive Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

Jun 16, 2025

Primary completion

Nov 20, 2027

Study completion Nov 20, 2029

Sponsor

Lead sponsor
Henan Cancer HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Oct 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 2 study of ARX788 given every 6 weeks in HER2-positive, metastatic breast cancer patients.

Conditions

  • HER2-positive, Metastatic Breast Cancer

Interventions

  • ARX788Drug

    2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective remission rate (ORR)Time frame: up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.